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A case of a 14-year-old girl with a 2-year history of
peripheral and sacroiliac joint pain and gastroin-
testinal symptoms, secondary to enthesitis-related
arthritis, is presented along with the management.
Introduction
Previously considered a chronic condition,
enthesitis-related arthritis – a type of juvenile
idiopathic arthritis – may in some cases represent
a sensitivity-related illness and thus respond to
antigenic avoidance and remediation of biochem-
istry. Enthesitis-related arthritis is a rare but
serious cause of childhood disability and chronic
pain that often leads to continuing complications
in adult life. Forming a small (1–16%) subset of
children with juvenile idiopathic arthritis,
1,2
enthesitis-related arthritis patients typically
experience enthesitis and asymmetrical hip and
lower extremity arthritis.
3–5 Common systemic
features include acute iritis
6 and subclinical
inﬂammatory bowel disease (IBD),
7 while symp-
tomatic cardiac myopathies and pulmonary par-
enchymal disease occur less commonly.
1,8 Unlike
adult-onset spondyloarthropathies, sacroiliitis in
enthesitis-related arthritis tends to present years
after disease onset.
8
To meet International League of Associations
for Rheumatology (ILAR) classiﬁcation for
enthesitis-related arthritis, patients must have (1)
arthritis and enthesitis; or (2) arthritis or enthesitis
with at least two of the following:
￿ Acute, symptomatic anterior uveitis;
￿ Sacroiliac joint or lumbosacral pain;
￿ Male gender and age over 6 years;
￿ HLA-B27 genotype;
￿ First-degree relative with history of ankylosing
spondylitis (AS), enthesitis-related arthritis,
sacroiliitis with IBD, Reiter’s syndrome, or
acute anterior uveitis.
Exclusion criteria for enthesitis-related arthritis
include systemic juvenile idiopathic arthritis,
psoriasis, or two positive ﬁndings of IgM rheuma-
toid factor occurring three months apart.
9
Genetic factors are particularly signiﬁcant in
enthesitis-related arthritis as 80% of cases are
found to be HLA-B27 positive.
1 Possessing a
HLA-B27 genotype confers a 20-fold increase in
spondylopathy risk in Caucasian populations
10
and also increases risk of enthesitis-related arthri-
tis progression to AS.
11 Moreover, HLA-B27 is
implicated in cardiac,
12 pulmonary
10 and malig-
nant
13 complications of spondylopathies. While
multiple mechanisms have been proposed for
the role of HLA-B27 allotypes in triggering auto-
immunity,
10 research is still inconclusive on the
exact pathophysiology.
Extensive work has been done on the extent to
which genetics inﬂuence juvenile idiopathic
arthritis and spondylopathies
14,15 but environ-
mental parameters remain largely unexplored
due to the relative rarity of the condition and the
continuing re-classiﬁcation of juvenile idiopathic
arthritis. Preliminary evidence implicates the
absence of breastfeeding, maternal smoking,
16
and infection – particularly streptococcus and
Epstein-Barr virus – in the development of juven-
ile idiopathic arthritis,
17 but further inquiry is
needed. Although children with juvenile idio-
pathic arthritis are known to be at risk for malnu-
trition, nutritional studies have focused on BMI
rather than speciﬁc biochemical deﬁciencies.
18
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CASE REPORT
1Management of enthesitis-related arthritis
Non-steroidal anti-inﬂammatory drugs (NSAIDs)
remain the ﬁrst-line treatment for enthesitis-
related arthritis, while metrotrexate and sulfasala-
zine are often introduced in the early stages for
better symptom control.
19 AntiTNF-alpha bio-
logics, particularly etanercept,
3 are increasingly
used in paediatric autoimmune disease. While
generally well-tolerated, gastrointestinal symp-
toms including nausea, vomiting and abdominal
pain are a signiﬁcant adverse effect of all of
these options,
3,20 often complicated by inﬂam-
mation due to disease activity.
21
Beyond gastrointestinal symptoms, each of these
medications has signiﬁcant side-effect proﬁles.
NSAIDs are also associated with nephrotoxicity,
headaches and behavioural changes, while metho-
trexate may cause (largely reversible) liver tox-
icity.
4,22,23 Other reported adverse effects of
methotrexate include loss of appetite, alopecia,
malaise, leucopenia,
19,24 and one case each of intes-
tinal sprue
25 and skin toxicity.
26 Sulfasalazine may
cause hepatitis, nephritis,
27 and haematologic
abnormalities,
28 although these are all uncommon.
29
Meanwhile, antiTNF-alpha agents have been
recently correlated to higher incidences of cancer
in adults
30 as well as paediatric malignancy.
31
Although autoimmunity confers an innate predis-
position to malignancy, genotoxic effects from
antiTNF-alpha therapy in juvenile idiopathic arthri-
tis have been shown to extend beyond pre-existing
DNA damage.
32 Rarer events include possible
increased occurrence ofCrohn’sdiseasewith etaner-
cept (although no conclusive link has been estab-
lished).
33 Finally, steroids are avoided when
possible, due to the well-known potential effects
on bone density, mental health, weight and
growth.
34,35
Treatment outcomes vary. Although patients
with juvenile idiopathic arthritis often achieve
high educational and employment levels,
36
overall quality of life is most dependent on
disease subtype, activity and progression.
37
One-third of juvenile idiopathic arthritis patients
experience disease continuing into adulthood
with full remission rates ranging from 87% in oli-
goarthritisto 17–33.4% in enthesitis-related arthri-
tis.
2,38 Unfortunately, progression to AS occurs in
39–75% of enthesitis-related arthritis cases
3,39
even with the advent of new therapies. Though
evidence on safety and efﬁcacy is mixed,
40–42
what is certain is that the long-term consequences
of new immunosuppressive and biologic thera-
pies in juvenile idiopathic arthritis will not be
clear for another generation and caution must be
exercised.
Case report
A 14-year-old girl with a history of enthesitis-
related arthritis presented to an environmental
medicine clinic, seeking adjunctive therapy for
complications of her illness. An extensive history,
physical exam, environmental assessment
43 and
series of laboratory tests
44 were performed.
Sixteen months prior, the previously healthy
patient had presented to a family physician with
a one-week history of sudden-onset right knee
pain. A joint aspirate was inconclusive for viral
infection and naproxen was prescribed for pain
control. Early investigations showed a positive
result for antinuclear antibody and an elevated
CRP (result 86.6 mg/L with normal 0–8 mg/L).
Results were negative for Streptococcus, Lyme
and Bartonella exposure. Family history included
ulcerative colitis in her father, and paternal grand-
father, although neither had sacroiliitis.
Over the next month, symptoms progressed to
include stiffness and soreness in her lower back,
bilateral knees and hips, right wrist and right
ﬁrst interphalangeal joint, at which point rheuma-
tology was consulted and diagnosed enthesitis-
related arthritis, although HLA-B27 testing was
not done. Visualizing persistent joint effusions
on ultrasound, the rheumatologist began metho-
trexate and what would become a ﬁve-month
course of prednisone in addition to Naproxen.
Sulfasalazine treatment began 14 months after
disease onset, as the patient experienced increas-
ing difﬁculty swallowing pills.
Although the patient noted some improvement
with medications, soreness and stiffness remained
in her back and affected joints. Intra-articular
steroid injections were associated with improved
function in her right wrist and thumb, and phy-
siotherapy and occupational therapy were
beneﬁcial, but pain continued to limit her partici-
pation in sports and school activities. Schoolwork
was also difﬁcult as she was right-handed. Signiﬁ-
cant medication-related nausea and abdominal
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2discomfort were only minimally lessened with
antiemetic medication – ondansetron. However,
the patient stated that compliance with ondanse-
tron was poor as the sight of any pill became
associated with nausea. Moreover, the course of
prednisone had resulted in a 20 lb weight gain,
about which the adolescent patient was quite self-
conscious. While moderately satisﬁed with con-
ventional treatment, the family regularly sought
out alternative therapies such as craniosacral
therapy and reﬂexology; these interventions were
felt to be minimally helpful.
Medical records from the environmental health
clinic revealed that physical exam was unremark-
able aside from a high BMI, and exposure history
was typical for a North American teenager.
However, biochemical analysis showed severe
nutritional abnormalities including low serum
levels of tryptophan, taurine and glutamic acid,
and low blood levels of zinc and copper. Serum
levels of sulfate, co-enzyme Q10, alpha-
tocopherol, vitamin A, B-carotene, and
25-hydroxy-vitamin D were also markedly low.
Toxicant analysis revealed elevated arsenic and
mercury levels in whole blood, as well as the pres-
ence of two fungal mycotoxins – ochratoxins and
tricothecenes in urine testing – suggesting a
history of mold exposure. In light of the predni-
sone exposure, bone density analysis was con-
ducted and found low – normal levels in the
patient’s hip and spine (total hip z-score –1.2;
total spine z-score –0.9).
Given the evidence of toxicant bioaccumula-
tion, it was hypothesized that the mechanism for
development of enthesitis-related arthritis in this
case might be related to epigenetic determinants
and sensitivity-related illness
45 – a disease mech-
anism initially described in the literature by
Claudia Miller in a 1996 paper in Toxicology
46
and thought to be mediated primarily through
the action of pro-inﬂammatory cytokines.
45
Accordingly, proposed treatment focused on: (1)
removing agents recognized as common antigenic
triggers; (2) restoring nutritional adequacy; and
(3) intervening to remove the bioaccumulated tox-
icants such as mycotoxins and other toxic
elements.
45 This approach has proven worthwhile
with other immune-related conditions.
47
Gluten and casein are commonly linked to
sensitivity-related illnesses,
48 and were thus elimi-
nated from the patient’s diet along with reﬁned
sugar, artiﬁcial sweeteners, ﬂavouring agents
and corn. Next, initial supplementation focused
on vitamin D, zinc, copper, DHA, strontium,
vitamin K2, magnesium and probiotics, due to
the following indications:
(1) Vitamin D deﬁciencies are linked to auto-
immune rheumatic disease in adults,
49 and
adequate levels are known to be anti-
inﬂammatory;
50–52
(2) Copper and zinc play signiﬁcant roles as co-
factors in normal immune functioning
53–55
and deﬁciencies are linked to gut inﬂam-
mation.
56 Furthermore, copper and zinc
deﬁciencies are associated with rheumatoid
arthritis;
57,58
(3) Though evidence for probiotics is not yet con-
clusive,
59 they may decrease gut inﬂam-
mation,
60–62 improve arthralgias,
63 and
improve gut barrier function.
64
As the combination of steroid treatment and
juvenile idiopathic arthritis are known to predis-
pose patientsto a higher lifetime riskof osteoporo-
sis,
65,66 a series of agents were targeted at bone
health. Studies support the use of strontium, mag-
nesium and vitamin D, and to a lesser extent,
vitamin K2 and DHA in increasing osteoblast
activity and restoring bone density.
67–73 Zinc and
copper are increasingly recognized as important
co-factors in preventing osteoporosis as well.
74,75
Within one month, the patient saw signiﬁcant
improvements in function that allowed her to
decrease, and then completely discontinue the
methotrexate, sulfasalazine, naproxen and ondan-
setron after six months. At six months, antinuclear
antibody testing was repeated and found to be
negative, and CRP levels had returned to normal
(result 1.0 mg/L), supporting the clinical picture
of inactive disease. Two months after discontinu-
ation, the patient reported that her functioning
and quality of life were ‘just like before’ the
onset of enthesitis-related arthritis, and she was
fully participating in gym class without any con-
cerns. She had lost the excess weight, was taking
guitar lessons without further wrist or ﬁnger
symptoms, and found the diet and lifestyle
changes ‘more than worth it’ for the health she
was experiencing. At 13 months post intervention,
the patient remains completely well with no recur-
rence of symptoms. Follow-up will continue with
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3the environmental health specialist to address the
xenobiotics found on toxic elements and myco-
toxin analysis – the suspected factors likely
involved in the initiation of sensitivity-related
illness in this patient.
Discussion
By the Wallace criteria, true remission of disease
cannot be declared until the patient has been com-
pletely asymptomatic without medication for 12
months with no active arthritis; no fever, rash, sero-
sitis, splenomegaly, or generalized lymphadenopa-
thy attributable to juvenile idiopathic arthritis; no
active uveitis; normal erythrocyte sedimentation
rate (ESR) or CRP and a physician’s global assess-
ment of disease activity.
38 As the patient has been
asymptomatic for over 12 months, she can be con-
sidered to be in full remission as she meets all
criteria.
Nevertheless, to the authors’ knowledge, this is
the ﬁrst reported caseof amelioration of enthesitis-
related arthritis symptoms after treatment with
dietary changes and nutritional supplementation.
While studies have focused on speciﬁc areas of
nutritional deﬁciency related to juvenile idio-
pathic arthritis,
17,18,50,76 no treatment strategy has
targeted environmental factors as key to
enthesitis-related arthritis and its remission. Still,
a growing body of evidence suggests
sensitivity-related illness as a mechanism behind
many cases of autoimmune disorders.
45 It is
unknown to what degree the speciﬁc signs and
symptoms in this case are the direct result of
sensitivity-related inﬂammation or the secondary
result of disordered biology resulting from nutri-
tional deﬁciency. As maldigestion and malabsor-
pion are common problems associated with food
intolerance resulting from sensitivity-related
inﬂammation, nutritional deﬁciency ensues –
which may account for the malnutrition state in
many cases of enthesitis-related arthritis.
In the sensitivity-related illness model, a
patient’s genetic predisposition towards illness is
compounded by the accumulation of toxicants,
including toxic elements
77,78 and mycotoxins.
79,80
Each toxicant may impact immune system func-
tioning, cumulating in sensitivity towards agents
that are typically well-tolerated (such as casein
and gluten). In response, autoantibodies
form
45,78 to tissues including that of the joints
and the gut,
81 leading to the presenting symp-
toms. Mycotoxins
80 and medications
59 alike may
be determinants in gut inﬂammation. Inﬂam-
mation leads to impairment in absorption of nutri-
ents necessary for healthy immune function and
excretion of toxic substances (Table 1), further
worsening symptoms.
45,46,82,83
Although enthesitis-related arthritis is not
usually treated as a sensitivity-related illness,
cases of SLE
90 and of polyarticular juvenile idio-
pathic arthritis
45 have been reported that are
either result from, or are resolved through
environmental manipulation. While more rigor-
ous study is needed to elucidate the pathways
behind the development of enthesitis-related
arthritis and to derive consensus conclusions
that can be generalized, individual patients may
beneﬁt from an environmental medicine approach
to their disease. Although one case is insufﬁcient
to draw ﬁrm conclusions as spontaneous remis-
sion is possible, the complete resolution of signs
Table 1
Micronutrient deﬁciencies identiﬁed in the
patient
Deﬁciencies Signiﬁcance
Coenzyme Q10 Electron transport chain; ATP
production in aerobic
respiration
Sulphate Glutathione production,
allowing for heavy metal
detoxiﬁcation through
direct conjugation, free
radical neutralization,
antioxidant properties
84
Tryptophan Production of serotonin,
melatonin, and
endogenous source of
niacin
Taurine Anti-inﬂammatory
properties, antioxidant;
blood pressure
regulation
85
Glutamic acid Neurotransmitter
Alpha-tocopherol Antioxidant;
86 inhibits mast
cell and eosinophil
proliferation
87
Vitamin A/
Beta-carotene
Anti-inﬂammatory;
88,89
increases Th2 response,
decreases Th1
87
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4and symptoms occurring within short order after
directed interventions were commenced suggests
that such an approach warrants further investi-
gation in other patients.
Conclusion
In this case report, a patient with a two-year
history of enthesitis-related arthritis experienced
a total resolution of symptoms after avoiding
certain inciting antigens and correcting her nutri-
tional deﬁciencies. Although the conventional
approach to enthesitis-related arthritis manages
to control patient symptoms and maintain func-
tion, years of chronic disease and reliance on
medications is not ideal if remission is possible
with less toxic measures. Enforcing dietary
changes and taking required supplements to
address speciﬁc nutritional deﬁciencies requires
a high level of commitment on the part of patients
and their families, but may offer a better quality of
life than the current standard of care. Thus, prior
to commencing potentially toxic pharmaceutical
interventions, the authors suggest that it is reason-
able to consider a detailed assessment and
remediation of nutritional biochemistry; an eight-
week trial of avoidance of common inciting anti-
gens; and exploration and management of any
underlying bio-accumulated toxicant load result-
ing from adverse environmental exposures.
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